Societe Generale’s Madrigal Pharmaceuticals MDGL Stock Holding History

Societe Generale’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$15K	Buy	+1,675	New	+$20.1K	﹤0.01%	2521

Other funds holding MDGL

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Societe Generale's MDGL Position: Q2 2016 in Review

Societe Generale opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2016: 1,675 shares worth $15K. The stake represents ﹤0.01% of the portfolio and ranks #2521 among its holdings.

55 funds tracked by Wall St. Rank hold MDGL as of Q2 2016.

Societe Generale held 1,675 shares of Madrigal Pharmaceuticals worth $15K as of Q2 2016.
Madrigal Pharmaceuticals was a new Societe Generale position in Q2 2016.
Madrigal Pharmaceuticals made up ﹤0.01% of Societe Generale's portfolio in Q2 2016, its #2521 holding.
55 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.